FORM D

Notice of Exempt Offering of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

AMISSION	Expires
.C.	Estima
	per res

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity CIK (Filer ID Number) Previous Name(s) None None 0001517681 **Propanc Health Group** Corporation Name of Issuer **Propanc Health Group** Propanc Biopharma, Inc. Corp Jurisdiction of Incorporation/Organization DELAWARE Year of Incorporation/Organization • Over Five Years Ago • Within Last Five Years (Specify Year)

• Yet to Be Formed

Entity Type

Θ	Corporation
0	Limited Partnership
0	Limited Liability Company
0	General Partnership
0	Business Trust
0	Other

2. Principal Place of Business and Contact Information

Name of Issuer			
Propanc Biopharma, Inc.			
Street Address 1	Str	eet Address 2	
302, 6 BUTLER STREET			
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
CAMBERWELL, VIC	AUSTRALIA	3124	310-402-2681

3. Related Persons

Last Name	First Name		Middle Name		
Nathanielsz	James				
Street Address 1		Street Address 2	-		
302, 6 Butler Street					
City	State/Province/O	Country	ZIP/Postal Code		
Camberwell, VIC	AUSTRALIA		3124		
Relationship: 🔽 Execut	ive Officer	Director	Promoter		
Clarification of Response (if Necessary	y)				
Last Name	First Name		Middle Name		
Kenyon	Julian				
Street Address 1		Street Address 2			
302, 6 Butler Street					
City	State/Province/C	Country	ZIP/Postal Code		
Camberwell, VIC	AUSTRALIA		3124		

|--|

Clarification of Response (if Necessary)

4. Industry Group

C Agriculture

Banking & Financial Services

- Commercial Banking
- **C** Insurance
- **C** Investing
- C Investment Banking
- C Pooled Investment Fund
- Other Banking & Financial
- C Services

C Business Services

Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation C Environmental Services
- C Oil & Gas
- C Other Energy

Health Care

- Biotechnology
- C Health Insurance
- C Hospitals & PhysiciansC Pharmaceuticals
- C Other Health Care

C Manufacturing Real Estate

C

0

C Commercial

Construction

C REITS & Finance

C Other Real Estate

Residential

C Retailing

C Restaurants

Technology

- C Computers
- **C** Telecommunications
- C Other Technology

Travel

- C Airlines & Airports
- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel

C Other

5. Issuer Size **Revenue Range** Aggregate Net Asset Value Range C C No Revenues No Aggregate Net Asset Value C \$1 - \$1,000,000 \$1 - \$5,000,000 0 C C \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000 0 C \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000 C \$50,000,001 - \$100,000,000 C \$25,000,001 - \$100,000,000 C 0 Over \$100,000,000 Over \$100,000,000 \odot **Decline to Disclose** C **Decline to Disclose** C 0 Not Applicable Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505	
Rule 504 (b)(1)(i)	Rule 506(b)	
Rule 504 (b)(1)(ii)	□ Rule 506(c)	
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)	
	Investment Company Act Section 3(c)	

٦

Ē

New Notice Date of First Sale 2018-10-02				
Amendment				
8. Duration of Offering				
Does the Issuer intend this offering to last more than one year? C Yes No				
0. Type(a) of Securities Offered (select all that apply)				
9. Type(s) of Securities Offered (select all that apply)				
Pooled Investment Fund Equity				
Tenant-in-Common Securities 🔽 Debt				
Mineral Property Securities Option, Warrant or Other Right to Acquire Another Security				
Security to be Acquired Upon Exercise of Option, Warrant or Conter (describe) Other Right to Acquire Security				
10. Business Combination Transaction				

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? C Yes $^{\circ}$ No

Clarification of Response (if Necessary)

11. Minimum Investment

Minimum investment accepted from any outside s
0

12. Sales Compensation	
Recipient	Recipient CRD Number 🔲 None
(Associated) Broker or Dealer 🔲 None	(Associated) Broker or Dealer CRD 🔲 None
Street Address 1	Street Address 2
City State	/Province/Country ZIP/Postal Code
State(s) of Solicitation	All States

USD

13. Offering and Sales Amounts

Total Offering Amount	\$	422000	USD	Indefinite
Total Amount Sold	\$	422000	USD	
Total Remaining to be Sold	\$	0	USD	🗖 Indefinite
Clarification of Response (if Necessary)				

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,

Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to
persons who do not qualify as accredited investors, enter the total number
of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$	0	USD	Estimate
Finders' Fees \$	0	USD	Estimate
Clarification of Response (if Necessary)			

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

	\$ 0	USD	Estimate
Clarification of Response (if Necessary)			
Some of the proceeds to be used for general working capital purposes may include salaries and payments to officers and/or officials listed in Item 3.			

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Propanc Biopharma, Inc.	/s/ James Nathanielsz	James Nathanielsz	CEO, Chief Financial Officer and Chief Accounting Officer	2018-10-11